New blood test markers may spot pancreatic cancer earlier — and beat CA19-9 alone
A four-protein blood test detected 91.9% of pancreatic cancers and 87.5% of early-stage cases in stored samples, with a 5% false-positive rate, NIH researchers reported Friday. The panel combined two newly identified proteins with CA19-9 and THBS2. Researchers said larger, prospective studies are needed before clinical use. Routine screening for pancreatic cancer remains unrecommended for average-risk adults.